Shanghai RAAS Blood Products Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Shanghai RAAS Blood Products Co., Ltd. carries a market capitalization of 30.52B, placing it among publicly traded companies globally. Its enterprise value stands at 40.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 30.52B |
| Enterprise Value | 40.37B |
Share Statistics
Shanghai RAAS Blood Products Co., Ltd. currently has 6.64B shares outstanding.
| Shares Outstanding | 6.64B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shanghai RAAS Blood Products Co., Ltd. trades at a trailing price-to-earnings ratio of 43.23. The price-to-sales ratio is 8.13, and the price-to-book ratio stands at 2.13.
| PE Ratio | 43.23 |
| PS Ratio | 8.13 |
| PB Ratio | 2.13 |
| P/TBV Ratio | 1.62 |
| P/FCF Ratio | 103.85 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shanghai RAAS Blood Products Co., Ltd. trades at an EV/EBITDA multiple of 42.40 and an EV/FCF ratio of 95.89. The EV/Sales ratio of 8.56 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 42.40 provides insight into valuation relative to core operating earnings.
| EV / Sales | 8.56 |
| EV / EBITDA | 42.40 |
| EV / EBIT | 42.40 |
| EV / FCF | 95.89 |
Financial Position
Shanghai RAAS Blood Products Co., Ltd. maintains a current ratio of 3.73, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.16, indicating elevated leverage, while an interest coverage ratio of 14.72 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.73 |
| Quick Ratio | 0.67 |
| Debt / Equity | 12.16 |
| Debt / EBITDA | 4.15 |
| Interest Coverage | 14.72 |
Financial Efficiency
Shanghai RAAS Blood Products Co., Ltd. posts a return on equity of 5.05 and a return on invested capital of 2.22.
| Return on Equity (ROE) | 5.05 |
| Return on Assets (ROA) | 2.44 |
| Return on Invested Capital (ROIC) | 2.22 |
| Return on Capital Employed (ROCE) | 4.80 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.61 |
Taxes
Over the trailing twelve months, Shanghai RAAS Blood Products Co., Ltd. has paid 211.67M in income taxes, reflecting an effective tax rate of 19.29.
| Income Tax | 211.67M |
| Effective Tax Rate | 19.29 |
Stock Price Statistics
Shanghai RAAS Blood Products Co., Ltd.'s stock has declined approximately -32.30994% over the past 52 weeks. The 50-day moving average sits at 5.14, while the 200-day moving average is 6.07.
| Beta (5Y) | N/A |
| 52-Week Price Change | -32.30994% |
| 50-Day Moving Average | 5.14 |
| 200-Day Moving Average | 6.07 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanghai RAAS Blood Products Co., Ltd. generated 4.71B in revenue and converted that into 885.92M in net income, yielding earnings per share of 0.13. EBITDA reached 952.01M, while operating income came in at 952.01M.
| Revenue | 4.71B |
| Gross Profit | 1.77B |
| Operating Income | 952.01M |
| Pretax Income | 1.10B |
| Net Income | 885.92M |
| EBITDA | 952.01M |
| EBIT | 952.01M |
| Earnings Per Share (EPS) | 0.13 |
Balance Sheet
Shanghai RAAS Blood Products Co., Ltd. holds 1.88B in cash and equivalents against 3.95B in total debt, resulting in a net debt position of 1.95B. Total book value stands at 17.97B, with working capital of 7.61B providing operational flexibility.
| Cash & Cash Equivalents | 1.88B |
| Total Debt | 3.95B |
| Net Debt | 1.95B |
| Equity (Book Value) | 17.97B |
| Book Value Per Share | 2.73 |
| Working Capital | 7.61B |
Cash Flow
After subtracting -368.74M in capital expenditures, free cash flow totaled -368.74M - equivalent to -0.06 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -368.74M |
| Free Cash Flow | -368.74M |
| FCF Per Share | -0.06 |
Margins
Shanghai RAAS Blood Products Co., Ltd. operates with a gross margin of 37.46, reflecting its pricing power and cost economics. The operating margin of 20.20 and net profit margin of 18.80 provide insight into operational efficiency.
| Gross Margin | 37.46 |
| Operating Margin | 20.20 |
| Pretax Margin | 23.28 |
| Profit Margin | 18.80 |
| EBITDA Margin | 20.20 |
Dividends & Yields
The company's payout ratio of 18.69 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.03 |
| Dividend Yield | N/A |
| Payout Ratio | 18.69 |
| Shareholder Yield | -7.53 |
| FCF Yield | 0.96 |
Stock Splits
Shanghai RAAS Blood Products Co., Ltd.'s most recent stock split took place on September 28, 2016 with a 5:9 split ratio.
| Last Split Date | 9/28/2016 |
| Split Ratio | 5:9 |
Scores
Shanghai RAAS Blood Products Co., Ltd. posts an Altman Z-Score of 5.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.34 |